![](/global-assets/2529/image-thumb__2529__default/container-bg-2.png)
Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)Ociperlimab
(anti-TIGIT)BG-685011
(CDK2 inhibitor)BGB-43395
(CDK4 inhibitor)BG-C90742
(B7H4-ADC)LBL-0073
(anti-LAG3)Surzebiclimab
(anti-TIM3)Umbrellaa
(IO combinations)Zanidatamab4
(anti-HER2 BsAb)BGB-A445
(anti-OX40)BGB-15025
(HPK1 inhibitor)BGB-26808
(HPK1 inhibitor)BGB-24714
(SMAC mimetic)BGB-30813
(DGKζ inhibitor)BGB-A3055
(anti-CCR8)BGB-10188
(PI3Kδ inhibitor)Pamiparib
(PARP 1/2 inhibitor)Tarlatamab5
(DLL3 x CD3)Xaluritamig5
(STEAP1 x CD3)Blinatumomab5
(CD3 x CD19)Goserelin microspheres6
(GnRH agonist)BGB-C354
(B7H3-ADC)BGB-B3227
(MUC1 x CD16A BsAb)BG-C477
(CEA-ADC)BGB-53038
(PanKRAS inhibitor 2G)BG-C137
(FGFR2b ADC)BGB-58067
(PRMT5 inhibitor)BG-60366
(EGFR-targeted CDAC)Safety and efficacy have not been established for investigational products and/or uses.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Zanubrutinib
(BTK inhibitor)Zanubrutinib
Immunology and Inflammation (BTK inhibitor)Sonrotoclax
(BCL2 inhibitor)BGB-16673
(BTK-targeted CDAC)BGB-21447
(BCL2 inhibitor)Tislelizumab
(anti-PD-1)Ociperlimab
(anti-TIGIT)Safety and efficacy have not been established for investigational products and/or uses.
aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.
bin combination with Zanubrutinib.
1Ensem collaboration; BeiGene has global rights.
2DualityBio collaboration; BeiGene has global rights.
3Leads Biolabs collaboration; BeiGene has ex-China commercial rights.
4Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights.
5Amgen collaboration; BeiGene has China commercial rights.
6Luye collaboration; BeiGene has China rights.
1L, first line; 2L, second line; 3L, third line; ADC, antibody-drug conjugate; BC, breast cancer; AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BsAb, bispecific antibody; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK, cyclin-dependent kinase; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FL, follicular lymphoma; gBRCAm, germline BRCA mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GnRH, gonadotropin-releasing hormone; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; LA, locally advanced; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; P13kδ, phosphoinositide 3-kinase-δ; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PSOC, platinum-sensitive ovarian cancer; RCC, renal cell carcinoma; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; Sq, squamous; STEAP1, six-transmembrane epithelial antigen of the prostate 1; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM3, T-cell immunoglobulin domain and mucin domain 3; TN, treatment naive; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.
Interactive Clinical Pipeline
Videos
Anti-OX40 Mechanism of Action
Anti-PD-1 Mechanism of Action
CDK4 Inhibitor Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action
PARPI Mechanism of Action